心脏瓣膜病介入治疗的现状和未来  

Current status and future of interventional therapy for valvular heart disease

作　　者：陈茂[1] 李侨[1] 熊恬园[1] CHEN Mao;LI Qiao;XIONG Tianyuan(Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China)

机构地区：[1]四川大学华西医院心脏内科,四川成都610041

出　　处：《西部医学》2021年第3期313-316,共4页Medical Journal of West China

基　　金：国家自然科学基金面上项目(81970325)。

摘　　要：心脏瓣膜病是一种常见的心脏疾病,一旦出现症状,尤其是合并心功能不全时,预后极差。既往外科修复和置换是瓣膜病主要的有效治疗手段,但随着全球人口老龄化,高龄瓣膜病患者日益增多,退行性病变以及功能性病变是高龄瓣膜病患者的主要病因,对于这部分人群,手术风险巨大,往往不能获得外科手术机会,因此瓣膜病介入治疗逐渐受到关注和发展。本文对心脏瓣膜病介入治疗的国内外发展现状做一述评,并对其在我国发展的未来作出展望。Valvular heart disease is a common heart disease,and the prognosis is poor once symptoms appear,especially when combined with cardiac failure.With the aging trend of the global population,the number of elderly valvular disease patients is increasing and degenerative diseases and functional lesions are the main causes of elderly valvular disease patients.Although surgical repair and replacement are the main effective treatment methods for valvular diseases,but for this group of people,surgical risks are very high,often cannot get the opportunity of surgery,so valvular disease intervention began to receive attention and development.In this paper,the development of interventional therapy for valvular heart disease abroad and at home are reviewed,and its future development in China is prospected.

关 键 词：心脏瓣膜病 介入治疗 经导管主动脉瓣植入术 经导管二尖瓣介入治疗 经导管肺动脉瓣植入术 经导管三尖瓣介入治疗 

分 类 号：R654.2[医药卫生—外科学]